Advaxis Inc. buy tamam
Start price
26.09.17
/
50%
€57.91
Target price
01.02.19
€58.18
Performance (%)
-91.14%
End price
01.02.19
€5.13
Summary
This prediction ended on 01.02.19 with a price of €5.13. The BUY prediction by tamam for Advaxis Inc. performed very badly with a performance of -91.14%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Advaxis Inc. | - | - | - | - |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by tamam for this prediction
In the thread Advaxis Inc. diskutieren
ADXS has very interesting make-or-break potential, caveat emptor!
One can be tentatively optimistic in the ability of ADXS to move the needle in its late-stage clinical programs. Cervical cancer remains a substantial unmet need, and the company is moving aggressively toward filing for approval in Europe. One highly encouraging sign, in my mind, is the tacit endorsement from 3 out of the 5 big immune checkpoint developers. BMY, MRK, and AZN are all collaborating with ADXS in some way. By no means is ADXS the only partner for the immune checkpoints, but this is a positive sign for me.
Cantor Fitzgerald reiterates buy rating with target of $19.00.
https://www.advaxis.com/wp-content/uploads/2017/06/A-recombinant-HER2-Neu.pdf
(Laufzeit überschritten)